Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 87.5%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Beta‐blockers vs placebo, no treatment or surveillance only · Clinically important non‐fatal end point as defined byShores 1994(aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery)
  Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
  RR 0.79 [0.37, 1.69]
  1 study · 70 participants
  Low
Related · question page
- Beta‐blockers vs placebo, no treatment or surveillance only · Acute aortic dissection
  Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
  RR 0.59 [0.12, 3.03]
  1 study · 70 participants
  Low
Related · question page
- Beta‐blockers vs placebo, no treatment or surveillance only · Cardiovascular surgery
  Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
  RR 0.59 [0.12, 3.03]
  1 study · 70 participants
  Low
Related · question page
- Beta‐blockers vs placebo, no treatment or surveillance only · Outcomes
  Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Beta‐blockers vs placebo, no treatment or surveillance only · All‐cause mortality
  Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
  RR 0.24 [0.01, 4.75]
  1 study · 70 participants
  Low

Beta‐blockers vs placebo, no treatment or surveillance only

Outcomes · people with confirmed diagnosis of Marfan syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Beta‐blockers vs placebo, no treatment or surveillance only

All‐cause mortality · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in all‐cause mortality compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 0.24 [0.01, 4.75]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Clinically important non‐fatal end point as defined byShores 1994(aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery) · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in clinically important non‐fatal end point as defined byShores… compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 0.79 [0.37, 1.69]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Acute aortic dissection · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in acute aortic dissection compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 0.59 [0.12, 3.03]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Aortic regurgitation · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in aortic regurgitation compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 1.19 [0.18, 7.96]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Congestive heart failure · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in congestive heart failure compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 1.19 [0.18, 7.96]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Cardiovascular surgery · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in cardiovascular surgery compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 0.59 [0.12, 3.03]
1 study · 70 participants
Low

Beta‐blockers vs placebo, no treatment or surveillance only

Aortic root diameter > 6 cm · people with confirmed diagnosis of Marfan syndrome

Beta‐blockers showed no clear difference in aortic root diameter > 6 cm compared with placebo, no treatment or surveillance only (low certainty).

1 finding from 1 review

Beta‐blockers for preventing aortic dissection in Marfan syndrome 2017 · Cochrane Headline outcomes only
RR 1.19 [0.08, 18.24]
1 study · 70 participants
Low